Halliburton Company vs Johnson & Johnson — how do they compare? Halliburton Company trades at $33.8 (market cap $28.03B), while Johnson & Johnson trades at $259.8 (market cap $630.94B). The key difference: Johnson & Johnson is far larger — about 22.5× Halliburton Company's market cap, and Johnson & Johnson pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| HAL | JNJ | |
|---|---|---|
Market Cap | $28.03B | $630.94B |
Sector | Energy | Health |
52-Week High | $42.98 | $267.24 |
52-Week Low | $20.50 | $172.78 |
Enterprise Value | $34.18B | $659.21B |
Dividend Yield | 2.02% | 2.05% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Trailing returns across standard periods
Latest headlines on both assets
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →